Invivyd, Inc. (IVVD) Stock Analysis & Investment Frameworks
Invivyd, Inc. (IVVD) stock analysis on Invetso. Review Invivyd, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Invivyd, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Invivyd, Inc. Key Financial Metrics
- Market Cap: $188.44M
- Revenue: $53.43M
- ROE: -59.73%
- ROIC: -59.39%
- Dividend Yield: N/A
About Invivyd, Inc.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Invivyd, Inc. Investment Frameworks
Invetso analyzes Invivyd, Inc. (IVVD) across the following frameworks:
- Invivyd, Inc. 10Y Growth Potential
- Invivyd, Inc. Scenario Analysis
- Invivyd, Inc. Risks & Opportunities
- Invivyd, Inc. Economic Moat
- Invivyd, Inc. Business Model
- Invivyd, Inc. Management
- Invivyd, Inc. SWOT Analysis
- Invivyd, Inc. Porter's 5 Forces
- Invivyd, Inc. PESTLE Analysis
- Invivyd, Inc. ESG Analysis